Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks Maribavir's Real-World success against Post-Transplant CMV

NCT ID NCT06677892

Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 11, 2026 · Updated 3 times

Summary

This study follows 75 adults who have had a stem cell or solid organ transplant and are being treated with maribavir for cytomegalovirus (CMV) infection. Researchers will track how well the drug clears the virus, how long treatment lasts, and any side effects. The goal is to see how maribavir works in everyday medical practice under Belgian reimbursement rules.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
maribavir
What this could lead to
If successful, this study could confirm that maribavir is a safe and effective option for treating CMV after transplant in real-world settings.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. CMV recurrence or drug resistance could still occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

66 people

The number who actually took part.

Started

Feb 2025

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants who had a CMV infection/disease after SOT/HSCT and who start maribavir, according to summary of product characteristics (SmPC) and in line with Belgian reimbursement criteria for maribavir will be included.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant signed an informed consent form. * Aged greater than or equal to (\>=) 18 years at the time of consent. * Received an HSCT/SOT. * Diagnosed with CMV infection/disease any time after the HSCT/SOT date. * Starting maribavir for the first time and in line with the Belgian reimbursement criteria. Exclusion Criteria: • Participant treated with maribavir before the start of the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cytomegalovirus (CMV) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cytomegalovirus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cytomegalovirus (CMV)

Contacts and locations

Locations

  • CHU UCL Namur - site Godinne

    Yvoir, 5530, Belgium

  • CHU de Liège - site Sart Tilman

    Liège, 4000, Belgium

  • Cliniques Universitaires Saint-Luc

    Brussels, 1200, Belgium

  • Hôpital Erasme

    Anderlecht, 1070, Belgium

  • Institut Jules Bordet

    Anderlecht, 1070, Belgium

  • UZA

    Edegem, 2640, Belgium

  • UZBrussel

    Jette, 1090, Belgium

  • UZGent

    Ghent, 9000, Belgium

  • UZLeuven

    Leuven, 3000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.